| 黄 健,邓宏伟,陈 丹,杨树林,石 明.普适泰与地奥司明对老年慢性前列腺炎患者血清和前列腺液中MIP-2和MIP-1α的影响[J].现代生物医学进展英文版,2017,17(25):4920-4923. |
| 普适泰与地奥司明对老年慢性前列腺炎患者血清和前列腺液中MIP-2和MIP-1α的影响 |
| Clinical Effect of Prostatil Combined with Diosmin on Chronic Prostatitis and Serum and Prostate Fluid Levels of MIP-2 and MIP-1α |
| Received:February 16, 2017 Revised:March 12, 2017 |
| DOI：10.13241/j.cnki.pmb.2017.25.029 |
| 中文关键词: 普适泰 地奥司明 慢性前列腺炎 巨噬细胞炎性蛋白-2 巨噬细胞炎性蛋白-1α |
| 英文关键词: Prostatil Diosmin Chronic prostatitis Macrophage inflammatory protein-2 Macrophage inflammatory protein-1α |
| 基金项目:四川省自然科学基金项目（11HF20194） |
|
| Hits: 304 |
| Download times: 274 |
| 中文摘要: |
| 摘要 目的：探讨普适泰联合地奥司明治疗老年慢性前列腺炎(CP)的临床效果及对患者血清和前列腺液巨噬细胞炎性蛋白-2(MIP-2)、巨噬细胞炎性蛋白-1α(MIP-1α)水平的影响。方法：选择我院2015年1月~2016年9月收治的126例老年CP患者，采取随机数字表将其分成两组。观察组(63例)给予普适泰联合地奥司明治疗，对照组(63例)予以普适泰治疗。记录比较两组临床疗效，治疗前后血清与前列腺液的MIP-2、MIP-1α水平；评价两组用药安全性。结果：治疗12周后，观察组总有效率为93.7%，较对照组明显升高(81.0%，P<0.05)。与治疗前对比，两组治疗12周后血清和前列腺液中MIP-2、MIP-1α水平均显著下降(P<0.01)；且观察组治疗12周后血清与前列腺液中MIP-2、MIP-1α水平均显著低于对照组同期(P<0.01)。两组不良反应发生率对比差异无统计学意义(P>0.05)。结论：普适泰联合地奥司明治疗老年CP/CPPS能更安全有效地改善患者的临床症状，可能与其显著降低血清和前列腺液中MIP-2、MIP-1α水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical effect of prostatil combined with diosmin on the elderly patients with chronic pro- statitis (CP) and the macrophage inflammatory protein-2 (MIP-2) and macrophage inflammatory protein-1α (MIP-1α) in prostate fluid and serum. Methods: 126 cases of elderly patients with CP in our hospital from January 2015 to September 2016 were selected and ran- domly divided into two groups. Prostatil combined with diosmin were provided to the patients in observation groups (63 cases) while the control group (63 cases) was treated by prostatil alone. The clinical effect, MIP-2, MIP-1α levels in the prostate fluid and serum before and after therapy as well as the incidence of adverse reactions were observed and compared between two groups. Results: At 12 weeks after treatment, the total effective rate of observation group was 93.7%, which was obviously higher than that of the control group (81.0%, P<0.05). The MIP-2 and MIP-1α levels in prostate fluid and serum of both groups at 12 weeks after therapy were significantly lower than those before therapy (P<0.01), which were significantly lower in the observation group than those of the control group at the same time (P<0.01). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Prostatil combined with diosmin could more safely and effectively improve the clinical efficacy in the treatment of elderly patients with CP/CPPS, which might be related to reduce the levels of MIP-2, MIP-1α in serum and prostatic fluid. |
|
View Full Text
View/Add Comment Download reader |
| Close |
